Travere Therapeutics, Inc. — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Travere reported Q3 2026 FILSPARI net product sales of $200.2M (120% YoY growth) with 1,932 new patient start forms in IgAN/FSGS. Nine-month FILSPARI sales totaled $446.4M (104% YoY growth). The company recognized a $113.1M in-process R&D (IPR&D) expense from its exclusive licensing agreement with Everest Medicines for civorebrutinib. CEO Eric Dube will transition to Bradley Campbell effective December 1, 2026. Cash position: $471.8M (cash + marketable securities).
Why this rating
Strong 120% FILSPARI growth is material (~15% of $1.3B market cap annually), offsetting $113M IPR&D charge. CEO transition and pipeline progress support long-term trajectory. Neutral near-term, positive fundamentals.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.